Earnings Call Summary | ZimVie(ZIMV.US) Q2 2024 Earnings Conference
Earnings Call Summary | ZimVie(ZIMV.US) Q2 2024 Earnings Conference
Adjusted EBITDA for Q2 2024 was $16.1 million, corresponding to a 13.8% margin.The following is a summary of the ZimVie Inc. (ZIMV) Q2 2024 Earnings Call Transcript:
以下是ZimVie Inc.（ZIMV）Q2 2024業績會議通話記錄概要：
Financial Performance:
金融業績：
ZimVie Inc. reported Q2 2024 revenue of $117 million with revenue growing across implants, biomaterials, and digital solutions.
Net sales for Q2 2024 were $116.8 million, a slight decrease of 1.5% in reported rates.
Adjusted EBITDA for Q2 2024 was $16.1 million, corresponding to a 13.8% margin.
Adjusted earnings per share for continuing operations were $0.13 per share in Q2 2024.
ZimVie Inc.報告2024年Q2營業收入爲11700萬美元，元件、生物材料和數字解決方案的營業收入均增長。
2024年Q2淨銷售額爲11680萬美元，在報告匯率中略有下降1.5%。
2024年Q2調整後的EBITDA爲1610萬美元，相應的利潤率爲13.8%。
2024年Q2持續經營活動的調整後每股收益爲0.13美元。
Business Progress:
業務進展：
ZimVie has seen strong commercial traction with its dental implant portfolio, particularly the TSX and T3 PRO, and received FDA clearance for its GenTek Restorative Components in the U.S.
The company drove growth in its biomaterials portfolio and continued to expand its offerings.
Significant growth was achieved in digital solutions, highlighted by over 20% growth in both implant Concierge service and surgical guide sales.
ZimVie introduced the RealGUIDE Software Version 5.4, enhancing safety, accuracy, and efficiency in dental procedures.
ZimVie已經在其牙種植產品系列中看到了強勁的商業推廣，尤其是在TSX和T3 PRO方面，並且在美國獲得了其GenTek修復元件的FDA認可。
該公司推動了其生物材料組合的增長，並繼續擴展其產品組合。
數字解決方案實現了顯著增長，其中包括種植物接待員服務和手術指南銷售均增長超過20%。
ZimVie推出了RealGUIDE軟件版本5.4，提高了牙科手術中的安全性、精度和效率。
Opportunities:
機會：
The broadening of the U.S. market for GenTek Restorative Components represents an opportunity to enhance market presence and sales.
Digital solutions and partnerships, like the new scanner partnership with Medit, are expected to expand ZimVie's addressable market and enhance product adoption.
GenTek修復元件在美國市場的擴大代表着增強市場存在感和銷售機會。
數字解決方案和夥伴關係（如與Medit的新掃描儀合作）預計將擴大ZimVie的可尋址市場並提高產品採用率。
Risks:
風險：
Pressures on capital sales, including oral scanners, continue to impact U.S. sales negatively, an ongoing trend noted in recent quarters.
對資本銷售的壓力，包括口腔掃描儀，繼續對美國銷售產生負面影響，這是最近幾個季度的持續趨勢。
More details: ZimVie IR
更多細節：ZimVie IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
